|drug400||BI 706321 Wiki||1.00|
|D011470||Prostatic Hyperplasia NIH||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
Description: Percentage of subjects hospitalized due to COVID-19Measure: COVID-19 hospitalization Time: 30 days
Description: COVID Ordinal Scale defined as: Death Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation) Hospitalized on non-invasive ventilation or high flow nasal cannula Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with limitation in activity (continued symptoms) Not hospitalized without limitation in activity (no symptoms)Measure: COVID-19 Ordinal Outcomes Scale Time: 30 days
Description: Symptoms severity of COVID-19 using Brescia-COVID Respiratory Severity Scale (BCRSS)/AlgorithmMeasure: Symptoms severity of COVID-19 Time: 30 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports